Anthera Pharmaceuticals (OTCMKTS:ANTH – Get Free Report) and LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.
Volatility and Risk
Anthera Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Anthera Pharmaceuticals and LENZ Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anthera Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| LENZ Therapeutics | 1 | 2 | 5 | 0 | 2.50 |
Valuation & Earnings
This table compares Anthera Pharmaceuticals and LENZ Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anthera Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
| LENZ Therapeutics | $19.09 million | 11.51 | -$82.13 million | ($3.60) | -1.95 |
Anthera Pharmaceuticals has higher earnings, but lower revenue than LENZ Therapeutics.
Profitability
This table compares Anthera Pharmaceuticals and LENZ Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anthera Pharmaceuticals | N/A | N/A | N/A |
| LENZ Therapeutics | -519.30% | -46.82% | -43.32% |
Insider & Institutional Ownership
54.3% of LENZ Therapeutics shares are held by institutional investors. 2.1% of Anthera Pharmaceuticals shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
LENZ Therapeutics beats Anthera Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
